Isabella M. ADHD Case Study: Predominantly Inattentive Presentation, Cognitive Disengagement Syndrome, Differentials and Treatment

Isabella M. Case Study: ADHD Predominantly Inattentive Presentation, Cognitive Disengagement Syndrome, Differentials and Treatment

Isabella M., 8, is evaluated for inattentiveness, inconsistent grades (B to D, weakest in math) and slow task initiation. Teachers report quiet disengagement, “zoning out” and repeated prompting since kindergarten, without disruptive or impulsive behavior. She has limited peer relationships and was teased on her soccer team. History includes birth at 36 weeks, early speech delay, mild gait awkwardness, difficulty with multipart directions and fears of storms, nightmares and caregiver absence (subthreshold for anxiety). Family history: maternal aunt with adult ADHD, maternal phobic anxiety, a great-grandfather who died by suicide and a father with childhood reading problems. SNAP-IV shows 7–9 inattentive and 0–2 hyperactive-impulsive symptoms; the CDI-2 shows mild depressive features; and cognitive disengagement syndrome symptoms are observed.

1. Which DSM-5-TR diagnosis best accounts for her symptoms? Give a criteria-based rationale.
2. Identify three differential diagnoses with rationales.
3. Analyze developmental, familial and educational contributing factors.
4. Which standardized rating scales and assessment tools are most appropriate?
5. Discuss two FDA-approved stimulants and two non-stimulants: mechanisms, indications and considerations.
6. Mention off-label uses of stimulants and managing side effects.
7. What behavioral, educational, parent-focused and pharmacological strategies are appropriate?

Original example for study purposes (about 1,760 words). Educational case analysis, not clinical advice. Check your course textbook for preferred tools and add it as a reference if required.

Introduction

Isabella M. is an 8-year-old third grader referred for inattention, inconsistent grades, slow task initiation and difficulty following instructions. She is quiet rather than disruptive, and her rating scales, history and observations point to a primarily inattentive pattern with features of cognitive disengagement. This paper presents a diagnostic formulation, differential diagnoses, contributing factors, assessment tools, pharmacological options and a multimodal treatment plan.

1. Primary Diagnosis: ADHD, Predominantly Inattentive Presentation

The diagnosis that best accounts for Isabella’s presentation is attention-deficit/hyperactivity disorder (ADHD), predominantly inattentive presentation (F90.0), moderate. The DSM-5-TR requires, for children under 17, at least six of nine inattention symptoms persisting for at least six months to a degree inconsistent with developmental level; several symptoms present before age 12; symptoms present in two or more settings; clear evidence of interference with social or academic functioning; and symptoms not better explained by another mental disorder (American Psychiatric Association [APA], 2022).

• Symptom count: parent and teacher SNAP-IV ratings endorse 7–9 inattentive symptoms but only 0–2 hyperactive-impulsive symptoms, meeting the inattentive threshold and fitting the predominantly inattentive presentation.
• Specific symptoms: failure to sustain attention, appearing not to listen when spoken to (“zones out”), failure to follow through on instructions and finish schoolwork, difficulty organizing tasks, avoidance of sustained mental effort (homework struggles), losing track of tasks and distractibility (staring out the window).
• Onset and duration: teachers report the pattern since kindergarten, well before age 12 and far longer than six months.
• Multiple settings: symptoms occur at home, at school and on her soccer team.
• Impairment: grades fluctuate from B to D, homework causes nightly conflict and peer relationships are limited.

Her intact engagement when discussing animals suggests that cognitive ability is adequate and that the problem is sustaining attention on less preferred tasks, which is typical of ADHD. The severity specifier of moderate reflects significant but not extreme impairment. Her prominent daydreaming, slow processing and mental fogginess are consistent with cognitive disengagement syndrome (CDS), formerly called sluggish cognitive tempo. CDS is not a DSM-5-TR diagnosis, but a 2023 expert work group recommended the new name and described it as a distinct but overlapping symptom set (Becker et al., 2023). It should be documented as a clinically important feature that may affect treatment response.

2. Differential Diagnoses

Specific learning disorder with impairment in mathematics. Isabella’s greatest struggles are in math, her father had reading difficulties and her early speech delay and difficulty following multistep directions suggest possible weaknesses in language or processing. A specific learning disorder could explain academic underperformance and could co-occur with ADHD. It should be considered and evaluated with standardized achievement testing; it would not fully explain inattention across settings, including soccer.

Anxiety disorder (for example, separation anxiety or generalized anxiety disorder). She has persistent fears of storms, nightmares and caregiver absence, and her mother has a phobic anxiety history. Worry can impair concentration and look like inattention. Currently her fears do not meet full criteria, so anxiety is not the primary diagnosis, but subthreshold anxiety should be monitored because it may worsen with academic stress and can be affected by stimulant treatment.

Depressive disorder (for example, persistent depressive disorder). Mild depressive features on the CDI-2, social withdrawal, passivity and low engagement raise this possibility, and the family history includes suicide in a great-grandfather. Depression can cause poor concentration and slowed thinking. Because her inattention has been present since kindergarten and she engages normally with interests, depression is less likely to be primary, but it should be monitored and reassessed, with safety screening at follow-up visits.

Other conditions to rule out include absence seizures (brief staring spells; an EEG is indicated if staring episodes are abrupt, frequent and unresponsive), hearing or vision problems, sleep disorders and language disorder given her early speech delay.

3. Developmental, Familial and Educational Factors

Developmental factors. Late-preterm birth at 36 weeks is associated with a modestly increased risk of attention and learning problems. Her early speech delay, mild gait awkwardness and difficulty following multipart directions suggest a neurodevelopmental profile that may include language processing weaknesses. These factors may help explain why multistep verbal directions in class are especially hard for her.

Familial factors. ADHD is highly heritable, and a maternal aunt was recently diagnosed with adult ADHD. A maternal history of phobic anxiety increases her risk for anxiety, which may explain her lingering fears. Her father’s childhood reading problems may reflect a heritable learning disability or second-language effects; if Isabella’s home is bilingual, language exposure should be considered in testing. Family stress around homework has created a negative cycle: her disengagement leads to parental frustration, which leads to resistance, which further lowers motivation.

Educational factors. Third grade brings longer assignments, more independent work and more complex math, so demands now exceed her attention capacity. Because she is quiet rather than disruptive, her difficulties were easy to overlook, a common pattern in girls with inattentive ADHD that delays identification. Repeated failure, teasing on her soccer team and limited friendships likely contribute to her mild depressive features and withdrawal.

These factors interact: neurodevelopmental vulnerability and genetic risk create the core attention problem, increasing academic demands expose it and negative social and family interactions add emotional strain that worsens engagement.

4. Rating Scales and Assessment Tools

• Vanderbilt ADHD Diagnostic Rating Scales (parent and teacher): map directly to DSM criteria, screen for common comorbidities (anxiety, depression, oppositional and conduct problems) and include performance items, which makes them recommended in primary care evaluation (Wolraich et al., 2019).
• SNAP-IV (already completed): useful for confirming symptom counts and for tracking treatment response over time.
• Conners 4 or Behavior Assessment System for Children (BASC-3): broad-band, normed measures from multiple informants to assess ADHD alongside emotional and social functioning.
• A CDS rating scale (for example, the Child Concentration Inventory): to measure cognitive disengagement symptoms separately from ADHD inattention, because CDS may predict internalizing problems and treatment response.
• Screen for Child Anxiety Related Disorders (SCARED) and CDI-2 follow-up: to quantify anxiety and depressive symptoms.
• Psychoeducational testing (for example, WISC-V for cognitive and processing-speed profile, and WIAT-4 or Woodcock-Johnson IV achievement tests): to evaluate a specific learning disorder in mathematics.
• Language evaluation (for example, CELF-5) given early speech delay, plus hearing and vision screening and an EEG if absence seizures are suspected.
• Behavior Rating Inventory of Executive Function (BRIEF-2): to assess organization, working memory and task initiation, which guide school accommodations.

5. FDA-Approved Medications for ADHD

Stimulants.

• Methylphenidate (for example, Concerta, Ritalin LA): blocks reuptake of dopamine and norepinephrine at the presynaptic transporters, increasing their availability in prefrontal circuits. Approved for ADHD in children 6 years and older and adults. Long-acting forms cover the school day; common effects include decreased appetite, insomnia, headache and stomachache.
• Lisdexamfetamine (Vyvanse), an amphetamine: a prodrug converted to dextroamphetamine, which blocks reuptake and promotes release of dopamine and norepinephrine. Approved for ADHD from age 6. The prodrug design gives smooth, long-lasting effects and may reduce misuse potential.

Clinical considerations for stimulants include screening for cardiac history and monitoring blood pressure, heart rate, height and weight; watching for worsening anxiety or tics; and counseling about the boxed warning for abuse, misuse and addiction, which the FDA updated in 2023 to strengthen warnings for all prescription stimulants (U.S. Food and Drug Administration [FDA], 2023). Stimulants are the most effective medications for core ADHD symptoms in children (Cortese et al., 2018).

Non-stimulants.

• Atomoxetine (Strattera): a selective norepinephrine reuptake inhibitor approved from age 6. Effects build over several weeks; it has a boxed warning for suicidal thinking in children and adolescents and may cause nausea and decreased appetite. It is useful when anxiety is present or stimulants are not tolerated.
• Guanfacine extended release (Intuniv): a selective alpha-2A adrenergic agonist that strengthens prefrontal signaling, approved for ages 6–17 as monotherapy or with stimulants. Side effects include sedation, fatigue and low blood pressure, and it must be tapered to avoid rebound hypertension.

Viloxazine extended release (Qelbree), approved in 2021, and clonidine extended release are additional non-stimulant options.

6. Off-Label Uses of Stimulants and Managing Side Effects

Stimulants are sometimes used off label for treatment-resistant depression (as augmentation), fatigue related to cancer or multiple sclerosis, apathy in neurocognitive disorders and attention problems after traumatic brain injury. Evidence for these uses is mixed, so they require careful risk-benefit discussion and monitoring.

Side effects can usually be managed without stopping treatment:

• Decreased appetite: give the dose after breakfast, offer a high-calorie breakfast and evening snack and track height and weight on growth charts.
• Insomnia: give the dose early in the morning, consider a shorter-acting formulation and teach sleep hygiene.
• Headache or stomachache: take with food and consider dose adjustment.
• Irritability or “rebound” in the late afternoon: adjust timing or add a small afternoon dose.
• Anxiety or tics: reduce the dose, switch stimulant class or consider a non-stimulant.
• Cardiovascular effects: check blood pressure and heart rate at baseline and each visit.

7. Treatment Strategies

The American Academy of Pediatrics recommends that children aged 6 to 11 with ADHD receive FDA-approved medication together with parent training in behavior management and/or behavioral classroom interventions, along with educational supports (Wolraich et al., 2019).

• Parent-focused: parent training in behavior management to replace nightly homework battles with structure, clear single-step instructions, praise for effort and a predictable homework routine with short work periods and breaks. Coaching on parent-child interaction would address the observed frustration-resistance cycle.
• Educational: a Section 504 plan or an IEP under Other Health Impairment if needed, with preferential seating, directions given one step at a time and checked for understanding, chunked assignments, extended time and a daily report card linking school and home. Targeted math intervention should follow if testing identifies a learning disorder.
• Behavioral and psychosocial: organizational skills training, social skills support and help joining structured activities that match her interests (for example, an animal-care club). Cognitive behavioral therapy can address anxiety and mild depressive features.
• Pharmacological: after shared decision-making with her parents, a trial of a long-acting methylphenidate, titrated using parent and teacher ratings. If stimulants are ineffective or worsen anxiety, atomoxetine or viloxazine would be reasonable alternatives. Mood and anxiety should be monitored at each visit.
• Follow-up: monthly visits during titration, then every three months, repeating rating scales and reviewing academic progress, sleep, appetite, growth and mood.

Conclusion

Isabella’s quiet, persistent inattention since kindergarten, across settings and with clear impairment, meets criteria for ADHD, predominantly inattentive presentation, with notable cognitive disengagement features. Comprehensive assessment should rule out a learning disorder, anxiety, depression and medical causes. A multimodal plan that combines medication, parent training, school supports and attention to her emotional well-being offers the best chance of improving her learning, relationships and confidence.

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

Becker, S. P., Willcutt, E. G., Leopold, D. R., Fredrick, J. W., Smith, Z. R., Jacobson, L. A., Burns, G. L., Mayes, S. D., Waschbusch, D. A., Froehlich, T. E., McBurnett, K., Servera, M., & Barkley, R. A. (2023). Report of a work group on sluggish cognitive tempo: Key research directions and a consensus change in terminology to cognitive disengagement syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 62(6), 629–645. https://doi.org/10.1016/j.jaac.2022.07.821

Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.-C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4

U.S. Food and Drug Administration. (2023). FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions

Wolraich, M. L., Hagan, J. F., Jr., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., Zurhellen, W., & Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), Article e20192528. https://doi.org/10.1542/peds.2019-2528

More model assignments posted today

• MTE/517 technology integration analysis
• Mission Model Canvas assignment
• Sarah child abuse ethics presentation
• Nursing ethics paper
• Holland RIASEC career fit discussion
• Erikson integrity vs. despair discussion
• Child development concept map